McDermott advises Sensorion on its collaboration with Cochlear

Overview


PARIS (20th December 2017) – Sensorion, a biotech company pioneering novel treatments for inner ear diseases, and Cochlear Limited, global leader in implantable hearing solutions, jointly announced a strategic collaboration focused on improving hearing outcomes in patients with cochlear implants. McDermott Will & Emery advised Sensorion.

The collaboration will evaluate therapeutic approaches using SENS-401 in combination with cochlear implants, with preclinical studies initiating in 2018, and potential clinical trials to begin as soon as 2019.

As part of this strategic collaboration, Cochlear will invest €1.6 million in shares of Sensorion. In exchange, Cochlear will receive a right of first negotiation for a global license to use SENS-401 in patients with certain implantable devices.

The McDermott Will & Emery advising Sensorion included Emmanuelle Trombe (Partner), Anne-France Moreau and Marion Abecassis.

About McDermott


McDermott Will & Emery is a premier international law firm with a diversified business practice. Numbering more than 1,000 lawyers, we have offices in Boston, Brussels, Chicago, Dallas, Düsseldorf, Frankfurt, Houston, London, Los Angeles, Miami, Milan, Munich, New York, Orange County, Paris, Seoul, Silicon Valley and Washington, DC. Further extending our reach into Asia, we have a strategic alliance with MWE China Law Offices in Shanghai.

Media Contacts